Marimastat

Marimastat
Clinical data
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	Development terminated?;
Identifiers
	IUPAC name N-[2,2-Dimethyl-1-(methylcarbamoyl)propyl]-2-[hydroxy-(hydroxycarbamoyl)methyl]-4- methyl-pentanamide;
CAS Number	154039-60-8 ;
PubChem CID	119031;
IUPHAR/BPS	5220;
DrugBank	DB00786 ;
ChemSpider	106358 ;
UNII	D5EQV23TDS;
ChEMBL	ChEMBL279785 ;
PDB ligand	097 (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID20165524 ;
Chemical and physical data
Formula	C15H29N3O5
Molar mass	331.413 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(NO)[C@@H](O)[C@H](C(=O)N[C@H](C(=O)NC)C(C)(C)C)CC(C)C;
	InChI InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1 ; Key:OCSMOTCMPXTDND-OUAUKWLOSA-N ;
	(what is this?) (verify)

Marimastat was a proposed antineoplastic drug developed by British Biotech. It acted as a broad-spectrum matrix metalloproteinase inhibitor.^[1]^[2]

Marimastat performed poorly in clinical trials,^[3] and development was terminated.^{[citation needed]}

References

^ "Marimastat". National Cancer Institute.
^ Millar, AW; Brown PD; Moore J; et al. (1998). "Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers". Br J Clin Pharmacol. 45 (1): 21–6. doi:10.1046/j.1365-2125.1998.00639.x. PMC 1873993. PMID 9489589.
^ Sparano, JA (2004). "Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196". J Clin Oncol. 22 (23): 4683–90. doi:10.1200/JCO.2004.08.054. PMID 15570070.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.